NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model

被引：1
|
作者：
Soulas, Caroline [1 ]
Lalanne, Ana [2 ]
Bonnafous, Cecile [1 ]
Hoffman, Caroline [2 ]
Bonnet, Elodie [1 ]
Dujardin, Arnaud [1 ]
Breso, Violette [1 ]
Blery, Mathieu [1 ]
Lantz, Olivier [2 ]
Remark, Romain [1 ]
Vivier, Eric [3 ]
Andre, Pascale [1 ]
机构：
[1] Innate Pharma, Marseille, France
[2] Inst Curie, Paris, France
[3] Ctr Immunol Marseille Luminy, Marseille, France
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-1690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1690
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Preclinical and phase-2 clinical study of valproic acid administered in combination with cisplatin and cetuximab in recurrent/metastatic head and neck cancer
    Budillon, Alfredo
    Zotti, Andrea I.
    Vitagliano, Carlo
    Di Gennaro, Elena
    Caponigro, Francesco
    [J]. CANCER RESEARCH, 2017, 77
  • [42] Histone deacetylase inhibition can revert induced resistance to immune checkpoint blockade in a mouse model of prostate cancer
    Rahmy, Sharif
    Lu, Xin
    [J]. JOURNAL OF IMMUNOLOGY, 2021, 206
  • [43] In vivo efficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer
    Sosa, Gustavo A.
    Bates, Amber M.
    Patel, Ravi
    Hernandez, Reinier
    Grudzinski, Joseph J.
    Marsh, Ian
    Bednarz, Bryan
    Pieper, Alexander
    Nystuen, Erin
    Emma, Sarah
    Sumiec, Elizabeth G.
    Weichert, Jamey P.
    Morris, Zachary S.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [44] Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
    Gavrielatou, Niki
    Vathiotis, Ioannis
    Aung, Thazin Nwe
    Shafi, Saba
    Burela, Sneha
    Fernandez, Aileen I.
    Moutafi, Myrto
    Burtness, Barbara
    Economopoulou, Panagiota
    Anastasiou, Maria
    Foukas, Periklis
    Psyrri, Amanda
    Rimm, David L.
    [J]. CANCER RESEARCH COMMUNICATIONS, 2023, 3 (04): : 558 - 563
  • [45] Expansion cohort validation of a clinical predictive model for head and neck cancer survival in patients treated with immune checkpoint inhibitors.
    Laliotis, Georgios I.
    Issa, Majd
    Klamer, Brett
    Karivedu, Vidhya
    Bhateja, Priyanka
    Dibs, Khaled
    Mladkova, Nikol
    Pan, Xueliang Jeff
    Old, Matthew O.
    Gamez, Mauricio
    Grecula, John C.
    Jhawar, Sachin R.
    Mitchell, Darrion L.
    Baliga, Sujith
    Carrau, Ricardo
    Rocco, James William
    Blakaj, Dukagjin
    Bonomi, Marcelo Raul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models (vol11, year2023, pade1)
    Kansal, V
    Burnbam, A. J.
    Kinney, B. L. C.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [47] Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer
    Zhang, Yuqing
    Kirane, Amanda
    Huang, Huocong
    Sorrelle, Noah B.
    Burrows, Francis J.
    Dellinger, Michael T.
    Brekken, Rolf A.
    [J]. MOLECULAR CANCER RESEARCH, 2019, 17 (02) : 348 - 355
  • [48] Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
    Yang, Fan
    Yuan, Chenyang
    Chen, Fanghui
    Qin, Zhaohui S.
    Schmitt, Nicole C.
    Lesinski, Gregory B.
    Saba, Nabil F.
    Teng, Yong
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [49] Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer
    Fan Yang
    Chenyang Yuan
    Fanghui Chen
    Zhaohui S. Qin
    Nicole C. Schmitt
    Gregory B. Lesinski
    Nabil F. Saba
    Yong Teng
    [J]. Journal of Experimental & Clinical Cancer Research, 43
  • [50] Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy
    Cohen, Roger
    Fayette, Jerome
    Posner, Marshall
    Lefebvre, Gautier
    Bauman, Jessica
    Salas, Sebastien
    Even, Caroline
    Seiwert, Tanguy
    Colevas, Dimitrios
    Jimeno, Antonio
    Saada, Esma
    Burtness, Barbara
    Andre, Pascale
    Paturel, Carine
    Bonnafous, Cecile
    Soulie, Anne-Marie
    Tirouvanziam-Martin, Anne
    Zerbib, Robert
    Boyer-Chammard, Agnes
    [J]. CANCER RESEARCH, 2018, 78 (13)
12345